top of page

Ergomed and Ferrer complete recruitment for Phase IIa insomnia clinical trial

Under Ergomed’s co-development agreement withFerrer, the Phase IIa clinical trial is a double-blind, randomised, placebo-controlled cross-over, dose finding study of two oral doses of lorediplon in adult patients with insomnia disorder.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page